Why Radiopharma Trials Require Skills Most Clinical Teams Don’t Have
.png)
Why Radiopharma Trials Require Skills Most Clinical Teams Don’t Have
Radiopharmaceutical trials can look familiar at first. They follow standard clinical phases, include defined endpoints, and often resemble oncology studies in structure. On paper, they fit within established development models. But in practice, they operate very differently.
Radiopharmaceutical development depends on a level of coordination and technical expertise that many clinical teams are not set up to support.
The Appearance of Familiarity
Radiopharmaceutical trials include many elements seen in oncology studies. These include defined patient populations, dosing strategies, safety monitoring, and imaging-based endpoints. Because of this, teams often approach them using standard clinical trial models. That is where challenges begin.
The structure may be familiar, but the way these trials are executed is not.
A Multi-Disciplinary System, Not a Single Workflow
Radiopharmaceutical trials bring together several specialized fields.
These include oncology, nuclear medicine, imaging, radiopharmacy, and radiation safety. Each area has its own workflows and constraints.
In Theragnostic development, imaging and treatment are directly connected. Imaging agents such as ⁶⁸Ga-PSMA and ⁶⁸Ga-DOTATATE are used to identify patients for therapies like ¹⁷⁷Lu-PSMA and ¹⁷⁷Lu-DOTATATE [1].
This creates a system where timing and coordination matter at every step. Teams are not working in sequence. They are working in parallel, and their activities must align. That level of coordination is not typical in standard oncology trials.
Operational Complexity Is Often Underestimated
Radiopharmaceuticals introduce practical constraints that affect daily execution. Many isotopes have short half-lives, which means they must be produced, delivered, and administered within a limited time window.
Sites also need to manage specialized handling procedures, radiation safety requirements, and coordination between imaging and treatment schedules. These factors reduce flexibility. A delay in imaging or dosing can affect the entire workflow and impact data quality.
Global analyses show that nuclear medicine depends on infrastructure, workforce, and coordination across systems [2]. In clinical trials, these dependencies are more pronounced.
The Skill Gap at the Site Level
Many clinical sites are highly experienced in oncology trials, but radiopharmaceutical studies require additional capabilities. Sites must be able to coordinate imaging and therapy schedules, handle and administer radiopharmaceuticals, maintain radiation safety compliance, and align multiple departments around a single protocol.
This goes beyond having the right equipment. It requires teams that understand how to operate within these constraints.
Workforce data shows that shortages in imaging professionals are affecting clinical capacity [4], while regulatory expectations emphasize consistency and technical quality in imaging and treatment delivery [3]. This creates a gap between what trials require and what many sites can consistently deliver.
Why Traditional Models Fall Short
Traditional clinical trial models assume that sites can operate independently within a defined protocol.
Radiopharmaceutical trials do not follow that pattern. They require close coordination across departments, precise timing linked to radionuclide properties, and a clear understanding of how imaging and therapy interact. Without this level of alignment, even well-designed trials can face delays or variability.
The challenge is not the scientific concept. It is translating that concept into consistent clinical execution.
The Role of Translational Expertise
Closing this gap requires more than additional resources.
It requires expertise that connects science with execution. Teams need to understand how radiopharmaceuticals behave within clinical workflows, where delays and risks are most likely to occur, and how site capabilities align with protocol requirements.
Radiopharmaceutical development sits at the intersection of biology, physics, and clinical operations [1]. Success depends on integrating these elements into a coordinated system.
Theragnostic Insight - Radiopharmaceutical trials are integrated clinical systems. Success depends on how well imaging, therapy, and workflows are aligned across specialized teams.
What This Means for Sponsors and Clinical Teams
For sponsors, planning should include early evaluation of site capability. This means assessing nuclear medicine readiness, understanding imaging capacity, and evaluating coordination across departments.
For clinical teams, success depends on building the right expertise and workflows. This may involve cross-functional training, stronger coordination between imaging and treatment teams, and clear operational planning aligned with protocol requirements.
What This Means for You
Radiopharmaceutical development is advancing quickly. The science is strong, and the opportunity is clear, but successful trials depend on more than protocol design.
They depend on the systems and expertise required to deliver those protocols in practice.
At Theragnostic Insights, we help teams align development strategy with real-world execution. By identifying gaps early and supporting site readiness, we help ensure that radiopharmaceutical trials are both scientifically sound and operationally feasible.
Because in Theragnostic development, expertise is essential.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation, from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
- The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
- Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
- Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
- Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
- Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
- Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
- Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
- One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
- The Dosimetry Dilemma: Why Many Sites Aren’t Ready for Radioligand Trials
- Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
- The Hidden Role of Radiation Safety in Clinical Trial Activation
- The Radiopharma Workforce Gap: Who’s Actually Running These Trials?
- The Infrastructure Nobody Funds: Why Clinical Trial Sites Are Missing From Radiopharma Investment
- Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
- Why Radiopharma Trial Timelines Are Harder to Predict Than Traditional Oncology Trials
- When Imaging Becomes the Bottleneck
- Where the Money Goes: Why Radiopharma Investment Isn’t Solving the Infrastructure Gap
- Why Radiopharma Trials Require Skills Most Clinical Teams Don’t Have
References:
[1] Zhang et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy
[2] International Atomic Energy Agency, 2024. Nuclear medicine in therapy and diagnosis. IAEA
[3] European Medicines Agency, 2024. Concept paper on the clinical evaluation of therapeutic radiopharmaceuticals in oncology. EMA
[4] American Society of Radiologic Technologists, 2024. Medical imaging workforce shortage white paper. ASRT
https://humanhealth.iaea.org/resources/portfolio/nmdi-nm-in-therapy.html?
https://www.nature.com/articles/s41392-024-02041-6?
